Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ibogaine/Microdosing

Ibogaine for Microdosing

2 papers and 0 clinical trials exploring ibogaine as a treatment for microdosing.

CompoundIndole Alkaloid

Ibogaine

A unique indole alkaloid with complex pharmacology, investigated primarily for its capacity to interrupt substance use disorders and withdrawal.

Full Ibogaine profile
IndicationAround 300 million people worldwide are affected by a variety of mental health conditions that microdosing may address.

Microdosing

Microdosing involves the regular consumption of sub-hallucinogenic doses of psychedelics, primarily for cognitive enhancement and emotional wellbeing. Although popularised through anecdotal reports, rigorous scientific evidence on its effects is still limited, pointing to a critical need for further research in this emerging field.

Full Microdosing profile

Academic Research

2 papers
Open Accessindividual

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

This case series (n=3) describes three people with persistent symptoms after traumatic brain injury or hypoxic brain injury who took a 6-week iboga microdosing protocol alongside psychotherapy and supportive care. All three reported marked improvement, and two said their symptoms had fully resolved at long-term follow-up, but the authors do not claim the treatment caused these changes.

Published
June 3, 2026
Journal
Frontiers in Pharmacology
Authors
Tabaac, B. J., Carhart-Harris, R. L., Yung, T.
Open Accessmeta

Ibogaine - A legacy within the current renaissance of psychedelic therapy

This review (2023) gives an overview of research into ibogaine. It details animal studies and the human use of ibogaine in stopping addiction. Studies are few and far between, and clinical trials are only now being started.

Published
April 1, 2023
Journal
Pharmacological Research
Authors
Mash, D. C.

Clinical Trials

0 trials

No clinical trials have been tagged with both Ibogaine and Microdosing yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Ibogaine papers Search all Microdosing trials Full Ibogaine profile Full Microdosing profile